The Cancer Letter wins investigative, design awards

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Cancer Letter won four 2018 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists:

  • Investigative Journalism, Newsletter/Trade Publications, first place, for “A Coup D’état, and a $12M Deal at the University of Utah,” by Paul Goldberg and Matthew Ong (The Cancer Letter, April 21, April 28, May 5, 2017)

  • Front Page Design, Newsletter/Trade Publications, first place, for “43 Years Later: A Redesign of The Cancer Letter,” By Jacqueline Ong and Katherine Goldberg

  • Photo Illustration, Newsletter/Trade Publications, first place, for “Oncology as Art in 2017,” by Katherine Goldberg

  • Series, Newsletter/Trade Publications, finalist, for “Real-World Data: A New Frontier in Cancer Bioinformatics,” by Matthew Ong (The Cancer Letter, June 2, June 9, 2017)

This is the first time The Cancer Letter has won design awards. Every week, our illustrator, Katherine Goldberg, offers a smart, irreverent take on events in oncology. Jacqueline Ong, our designer, undertook a snazzy redesign of the PDF version of The Cancer Letter.

Here are a few of The Cancer Letter’s award-winning covers:

Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login